We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Bydureon

News List

FDA Approves Pediatric Type 2 Diabetes Treatment americanpharmaceuticalreview
July 26, 2021
The U.S. FDA approved Bydureon and Bydureon BCise (exenatide extended-release) injection to be used in addition to diet and exercise to improve glycemic control (blood sugar levels) in pediatric patients 10 years or older with type 2 diabetes.
CFDA Approves New Once-Weekly Bydureon(R) to Improve Glycemic Control in Type-2 Diabetes Patients prnasia
January 05, 2018
3Sbio Incannounced today that China's first Glucagon-like peptide-1 receptor agonist weekly preparation Bydureon® has been formally approved by China Food and Drug Administration , as a new treatment option to improve glycemic control for patients with ty
New injectable Bydureon BCise for type-2 diabetes patients approved by FDA pharmaasia
October 31, 2017
New Bydureon formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight loss.